Dose intensification in small cell lung cancer chemotherapy

Bibliography

• BORING CC, SQUIRES TS, TONG T: Cancer Statistics. CA Cancer J. Clin. (1993) 43:7–26.
   PubMed Web of Science ®Google Scholar
• GURNEY H, DODWELL D, THATCHER N, et al.: Escalating drug delivery in cancer chemotherapay: review of concepts and practice - part I. Ann. Oncol. (1993) 4:23–34.
   PubMed Web of Science ®Google Scholar
• ••Summarises the theoretical basis for dose intensification.
   Google Scholar
• WOLL PJ, HODGETTS J, LOMAX Let al.: Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor A randomised controlled trial of lenograstim in small-cell lung cancer. J. Clin. Oncol. (1995) 13:652–659.
   PubMed Web of Science ®Google Scholar
• ARRIAGADA R, LE CHEVALIER T, PIGNON JP, et al.: Initial chemotherapy doses and survival in patients with limited small-cell lung cancer. New Engl. J. Med. (1993) 329:1848–1852.
   PubMed Web of Science ®Google Scholar
• ••One of the first prospective studies to demonstrate a survival benefit wth intensifiedtreatment.
   Google Scholar
• STEWARD WP, VON PAWEL J, GATZMEIER U, et al.: Effects of GM-CSF and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomised study of 300 patients. J. Clin. Oncol. (1998) 16:642–650.
   PubMed Web of Science ®Google Scholar
• •Shows a survival benefit for intensified VICE.
   Google Scholar
• SOUHAMI RL, LAW K: Longevity in small-cell lung cancer. Br. J. Cancer (1990) 61:584–589.
   PubMed Web of Science ®Google Scholar
• LORIGAN P, MING LEE S, BETTICHER D, et al.: Chemotherapy with vincristine/ifosfamide/carboplatin/etoposide in small cell lung cancer. Semin. Oncol. (1995) 7:32–41.
   Google Scholar
• •Concise review of combination chemotherapy.
   Google Scholar
• PIGNON JP, ARRIAGADA R, IHDE D, et al.: A metaanalysis of thoracic radiotherapy for small cell lung cancer. New Engl. J. Med. (1992) 327:1618–1624.
   PubMed Web of Science ®Google Scholar
• •Demonstrates the survival advantage for thoracic radiotherapy.
   Google Scholar
• GREGOR A, CULL A, STEPHENS RJ, et al.: Effect of prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC): results of a UKCCCR/EORTC randomised trial. Proc. Am. Soc. Clin. Oncol. (1996) 15:381.
   Google Scholar
• ARRIAGADA R, LE CHEVALIER T, BORIE F, et al.: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J. Natl. Cancer Inst. (1995) 87:183–189.
   PubMed Web of Science ®Google Scholar
• WOLF M, HAVEMANN R, HOLLE R, et al.: Cisplatin/Etoposide versus ifosfamide/etoposide combination in small-cell lung cancer: a multicenter German randomized trial. J. Clin. Oncol. (1987) 5:1880–1889.
   PubMed Web of Science ®Google Scholar
• FELD R, EVANS WK, DEBOER G, et al.: Combined modality induction therapy without maintenance chemotherapy for small cell lung carcinoma. J. Clin. Oncol. (1984) 2:294–304.
   PubMed Web of Science ®Google Scholar
• AISNER J, WHITEACRE M, VAN ECHO DA, et al.: Adriamycin, cyclophosphamide and etoposide based combination chemotherapy studies for small-cell lung cancer. Lung Cancer (1988) 4:A110.
   Google Scholar
• JETT JR, EVERSON L, THERNEAU TM, et al.: Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin and vincristine with or without etoposide: a randomised trial of the North Central Cancer Treatment Group. J. Clin. Oncol. (1990) 8:33–38.
   PubMed Web of Science ®Google Scholar
• GATZMEIER U, HOSSFELD DK, NEUHASS R, et al.: Combination chemotherapy with carboplatin, etoposide and vincristine as first-line treatment in small-cell lung cancer. J. Clin. Oncol. (1992) 10:818–823.
   PubMed Web of Science ®Google Scholar
• SMITH IE, PERREN TJ, ASHLEY SA, et al.: Carboplatin, etoposide and ifosfamide as intensive chemotherapy for small-cell lung cancer. J. Clin. Oncol. (1990) 8:899–905.
   PubMed Web of Science ®Google Scholar
• PRENDIVILLE J, LORIGAN P, HICKS F, et al.: Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic radiotherapy and prophylactic cranial irradiation. Eur. J. Cancer (1994) 30A:2085–2090.
   Google Scholar
• GOODMAN GE, CROWLEY JJ, BLASKO JC, et al.: Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin and cyclophosphamide versus concurrent etoposide, vincristine doxorubicin and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group study. J. Clin. Oncol. (1990) 8:39–47.
   PubMed Web of Science ®Google Scholar
• MACBETH F, MILROY R, STEWARD W et al.: Lung Cancer: A Practical Guide to Management. Harwood Academic Publishers, Amsterdam (1992).
   Google Scholar
• PASS HI, MITCHELL JB, JOHNSON DH, et al.: Lung Cancer, Principles and Practice. Lippincott-Raven, Philadelphia (1996).
   Google Scholar
• SKIPPER HE, SCHABEL FM, Jr., MELLETT LB, et al.: Implications of biochemical, cytokinetic, pharmacologic and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother. Rep. (1970) 54:431–450.
   PubMedGoogle Scholar
• SCHABEL FM JR, GRISWOLD DP JR, CORBETT TH, et al.: Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Cancer (1984) 15:1160–1167.
   Web of Science ®Google Scholar
• DeVita VT, Jr., Hellman S, Rosenberg SA (Eds.), JB Lipincott, Philadelphia (1990):43–64.
   Google Scholar
• COLDMAN AJ, GOLDIE JH: Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin. Oncol. (1987) 4:29–33.
   Google Scholar
• KLASA RJ, MURRAY N, COLDMAN AJ: Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J. Clin. Oncol. (1991) 9:499–508.
   PubMed Web of Science ®Google Scholar
• DE VATHAIRE F, ARRIAGADA R, DE THE H, et al.: Dose intensity of initial chemotherapy may have an impact on survival in limited small cell lung carcinoma. Lung Cancer (1993) 8:301–308.
   Google Scholar
• SOUHAMI RL, RUDD R, RUIZ DE ELVIRA MC, et al.: Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign Trial. J. Clin. Oncol. (1994) 12:1806–1813.
   PubMed Web of Science ®Google Scholar
• SCULIER JP, RUDD R, RUIZ DE ELVIRA MC, et al.: Multiple drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a Phase III randomized study conducted by the European Lung Cancer Working Party. J. Clin. Oncol. (1993) 11:1858–1865.
   PubMed Web of Science ®Google Scholar
• DeVita VT, Jr., Hellman S, Rosenberg SA (Eds.), JB Lipincott, Philadelphia (1989):276–300.
   Google Scholar
• TRILLET-LENOIR V, GREEN J, MANEGOLD C, et al.: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur. J. Cancer (1993) 29A:319–324.
   PubMed Web of Science ®Google Scholar
• ••Evidence for G-CSF's ability to maintain dose intensity.
   Google Scholar
• THATCHER N, SAMBROOK R, STEPHENS RJ, et al.: First results of a randomised trial of dose intensification (DI) with G-CSF in small cell lung cancer (SCLC). Lung Cancer (1997) 1:7.
   Google Scholar
• FUKUOKA M, MASUDA N, NEGORO S, et al.: CODE chemotherapy with and withoutgranulocyte colony-stimulating factor in small-cell lung cancer. Br. J. Cancer (1997) 75:306–309.
   PubMed Web of Science ®Google Scholar
• BUNN PA, Jr., CROWLEY J, KELLY K, et al.: Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective Phase III randomised study of the Southwest Oncology Group. J. Clin. Oncol. (1995) 13:1632–1641.
   PubMed Web of Science ®Google Scholar
• PUJOL JL, DOUILLARD JY, RIVIERE et al.: Dose-intensity of a four drug chemotherapy with or without recombinant granulocyte-macrophage colony stimulating factor in extensive-stage small-cell lung cancer. J. Clin. Oncol. (1997) 15:2082–2089.
   PubMed Web of Science ®Google Scholar
• PACCAGNELLA A, FAVARETTO A, RICCARDI A, et al.: Granulocyte-macrophage colony stimulating factor increases dose intensity of chemotherapy in small-cell lung cancer. Cancer (1993) 72:697–706.
   PubMed Web of Science ®Google Scholar
• PETTENGELL R, WOLL PJ, O'CONNOR DA, et al.: Viability of haemopoietic progenitors from whole blood, bone marrow and leukapheresis product: effects of storage media, temperature and time. Bone Marrow Transplantation (1994) 14:703–709.
   PubMed Web of Science ®Google Scholar
• ••Introduces a novel and simpler method of stem cell support.
   Google Scholar
• WOLL PJ, LEE SM, LOMAX L, et al.: Randomised Phase II study of standard versus dose-intensive ICE chemotherapy with reinfusion of haemopoietic progenitors in whole blood in small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol. (1996) 333. Abstract 957.
   Google Scholar
• KUDOH S, SAWA T, KURIHARA Net al.: Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients. Cancer Chemother. Pharmacol. (1996) 38:S89–S95.
   PubMed Web of Science ®Google Scholar
• CRAWFORD J, GEORGE M: The role of haematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy. Semin. Oncol. (1995) 22:18–22.
   PubMed Web of Science ®Google Scholar
• TEPLER I, ELIAS L, SMITH JW, et al.: A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood (1996) 87:3607–3636.
   PubMed Web of Science ®Google Scholar
• DE CAMPOS E, RADFORD J, STEWARD W et al.: Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J. Clin. Oncol. (1995) 13:1623–1631.
   PubMed Web of Science ®Google Scholar
• •Reduced transfusion requirements in treated patients.
   Google Scholar
• CASE DC, BUKOWSKI RM, CAREY RW, et al.: Recombinant human erythropoietin therapy for anaemic cancer patients on combination chemotherapy. J. Natl. Cancer Inst. (1993) 85:801–806.
   PubMed Web of Science ®Google Scholar
• HARRIS LC, MARATHI UK, EDWARDS CC, et al.: Retroviral transfer of a bacterial alkyltransferase gene into murine bone marrow protects against chloroethylnitrosourea cytotoxicity. Clin. Cancer Res. (1995) 1:1359–1368.
   PubMed Web of Science ®Google Scholar
• LORD BI, DEXTER TM, CLEMENTS JM, et al.: Macrophage inflammatory protein protects multipotent haemopoietic cells from the cytotoxic effects of hydroxyurea in vivo. Blood (1988) 79:2605–2609.
   Google Scholar
• SLEVIN ML, STUBBS L, PLANT HJ, et al.: Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. Br. Med. J. (1990) 300:1458–1460.
   PubMed Web of Science ®Google Scholar
• ••Summary of patients' and health professionals' attitudes to chemotherapy.
   Google Scholar